Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Aurobindo looks for...

    Aurobindo looks for inorganic growth prospects in East Europe

    Written by Ruby Khatun Khatun Published On 2017-11-27T10:40:12+05:30  |  Updated On 18 Aug 2021 3:12 PM IST

    Mumbai: Hyderabad-based Aurobindo Pharma is looking at inorganic growth opportunities in Eastern Europe and other geographies for deeper market penetration and to secure newer technologies.


    Apart from acquisitions, the company is also keen to expand its product portfolio in the US and Western European markets with high-value drugs. The high-value products that are in the pipeline include oncology, hormones, depot injections, peptides, inhalers, patches and films, vaccines and biosimilars, the company said.


    "Our acquisition strategy will be largely on two platforms. One is to penetrate markets deeper and the other to secure newer technologies and platforms. We always maintain that anything that can come across in Eastern Europe will be prioritized," Aurobindo Pharma's managing director N Govindarajan said in an earnings presentation.


    But he was quick to add that there is no pressure on him to do an acquisition to fill any gap as "there are enough opportunities to grow organically".


    Earlier this year, the company announced the acquisition of Portugal's Generis Farmaceutica SA from Magnum Capital Partners for a consideration of Euro 135 million (around Rs 969 crore).


    The acquisition of Generis, by leveraging its strong portfolio and unrivaled brand recognition is expected to allow the company to establish itself as the top generics player in the Portuguese market.


    On product expansion into existing markets, he said, "The portfolio mix is complemented with the introduction of high-value products and the future pipeline that includes oncology, hormones, depot injections, peptides, inhalers, patches and films, vaccines and biosimilars."


    For FY18, it plans to spend about USD 130 million towards capex in vaccines and biosimilar.


    During the second quarter, its revenue rose 17 percent to Rs 4,436 crore driven by strong growth across key markets, boosting its bottom line by 29 percent to Rs 781 crore.


    Formulation business contributed 83 percent of total sales and with Rs 3,663 crore, registering a 22 percent growth. API business accounted for the balance of Rs 772 crore in Q2.


    In the formulations business, total sales from the US markets stood at Rs 2,099 crore, an increase of 21 percent year-on-year. The growth was primarily driven by new products and improved volumes of existing products.


    "We have launched eight products, including two injectables in the September quarter. Aurobindo USA has witnessed a growth of 37 percent in the quarter driven by new product launches and higher volume," Govindarajan said.


    The company has filed a total of 90 injectable ANDAs as of end September, of which 51 have already been approved-- two tentative approvals and the rest are under review with USFDA.


    He expects injectable business, which has already ramped up well, to grow by at least 40 percent this fiscal. But oral division disappointed with a price erosion of 9-11 percent.


    "Even though there is pressure, we still believe we would be able to grow our US business because there are a lot of opportunities for growing the volume as well to launch some new products," Govindarajan said.

    acquisitionsAurobindoAurobindo PharmaAurobindo Pharma LimitedbiosimilarsEast Europeindian pharma newsinorganic growthmarket penetrationN Govindarajanpharma newspharma news indiaprospectsTechnologiesUSFDAvaccines
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok